These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
272 related articles for article (PubMed ID: 19524696)
21. Behavioural state differentially engages septohippocampal cholinergic and GABAergic neurons in R6/1 Huntington's disease mice. Ransome MI; Hannan AJ Neurobiol Learn Mem; 2012 Feb; 97(2):261-70. PubMed ID: 22261461 [TBL] [Abstract][Full Text] [Related]
22. "Brain training" improves cognitive performance and survival in a transgenic mouse model of Huntington's disease. Wood NI; Glynn D; Morton AJ Neurobiol Dis; 2011 Jun; 42(3):427-37. PubMed ID: 21324361 [TBL] [Abstract][Full Text] [Related]
23. Age-dependent changes in the calcium sensitivity of striatal mitochondria in mouse models of Huntington's Disease. Brustovetsky N; LaFrance R; Purl KJ; Brustovetsky T; Keene CD; Low WC; Dubinsky JM J Neurochem; 2005 Jun; 93(6):1361-70. PubMed ID: 15935052 [TBL] [Abstract][Full Text] [Related]
24. Differential effects of voluntary physical exercise on behavioral and brain-derived neurotrophic factor expression deficits in Huntington's disease transgenic mice. Pang TYC; Stam NC; Nithianantharajah J; Howard ML; Hannan AJ Neuroscience; 2006 Aug; 141(2):569-584. PubMed ID: 16716524 [TBL] [Abstract][Full Text] [Related]
25. Effects of chronic stress on the onset and progression of Huntington's disease in transgenic mice. Mo C; Renoir T; Hannan AJ Neurobiol Dis; 2014 Nov; 71():81-94. PubMed ID: 25088714 [TBL] [Abstract][Full Text] [Related]
26. Early development of aberrant synaptic plasticity in a mouse model of Huntington's disease. Milnerwood AJ; Cummings DM; Dallérac GM; Brown JY; Vatsavayai SC; Hirst MC; Rezaie P; Murphy KP Hum Mol Genet; 2006 May; 15(10):1690-703. PubMed ID: 16600988 [TBL] [Abstract][Full Text] [Related]
27. Dendritic spine pathology and deficits in experience-dependent dendritic plasticity in R6/1 Huntington's disease transgenic mice. Spires TL; Grote HE; Garry S; Cordery PM; Van Dellen A; Blakemore C; Hannan AJ Eur J Neurosci; 2004 May; 19(10):2799-807. PubMed ID: 15147313 [TBL] [Abstract][Full Text] [Related]
29. Altered CB1 receptor and endocannabinoid levels precede motor symptom onset in a transgenic mouse model of Huntington's disease. Dowie MJ; Bradshaw HB; Howard ML; Nicholson LF; Faull RL; Hannan AJ; Glass M Neuroscience; 2009 Sep; 163(1):456-65. PubMed ID: 19524019 [TBL] [Abstract][Full Text] [Related]
30. Alterations in N-methyl-D-aspartate receptor sensitivity and magnesium blockade occur early in development in the R6/2 mouse model of Huntington's disease. Starling AJ; André VM; Cepeda C; de Lima M; Chandler SH; Levine MS J Neurosci Res; 2005 Nov; 82(3):377-86. PubMed ID: 16211559 [TBL] [Abstract][Full Text] [Related]
31. Dopamine release is severely compromised in the R6/2 mouse model of Huntington's disease. Johnson MA; Rajan V; Miller CE; Wightman RM J Neurochem; 2006 May; 97(3):737-46. PubMed ID: 16573654 [TBL] [Abstract][Full Text] [Related]
32. Deficits in spermatogenesis but not neurogenesis are alleviated by chronic testosterone therapy in R6/1 Huntington's disease mice. Hannan AJ; Ransome MI J Neuroendocrinol; 2012 Feb; 24(2):341-56. PubMed ID: 21988129 [TBL] [Abstract][Full Text] [Related]
33. Alterations in Hippocampal Inhibitory Synaptic Transmission in the R6/2 Mouse Model of Huntington's Disease. Dargaei Z; Liang X; Serranilla M; Santos J; Woodin MA Neuroscience; 2019 Apr; 404():130-140. PubMed ID: 30797895 [TBL] [Abstract][Full Text] [Related]
34. Phosphodiesterase type IV inhibition prevents sequestration of CREB binding protein, protects striatal parvalbumin interneurons and rescues motor deficits in the R6/2 mouse model of Huntington's disease. Giampà C; Middei S; Patassini S; Borreca A; Marullo F; Laurenti D; Bernardi G; Ammassari-Teule M; Fusco FR Eur J Neurosci; 2009 Mar; 29(5):902-10. PubMed ID: 19291221 [TBL] [Abstract][Full Text] [Related]
35. Early retinal function deficit without prominent morphological changes in the R6/2 mouse model of Huntington's disease. Ragauskas S; Leinonen H; Puranen J; Rönkkö S; Nymark S; Gurevicius K; Lipponen A; Kontkanen O; Puoliväli J; Tanila H; Kalesnykas G PLoS One; 2014; 9(12):e113317. PubMed ID: 25469887 [TBL] [Abstract][Full Text] [Related]
36. Clinico-pathological rescue of a model mouse of Huntington's disease by siRNA. Wang YL; Liu W; Wada E; Murata M; Wada K; Kanazawa I Neurosci Res; 2005 Nov; 53(3):241-9. PubMed ID: 16095740 [TBL] [Abstract][Full Text] [Related]
37. Impaired basal and running-induced hippocampal neurogenesis coincides with reduced Akt signaling in adult R6/1 HD mice. Ransome MI; Hannan AJ Mol Cell Neurosci; 2013 May; 54():93-107. PubMed ID: 23384443 [TBL] [Abstract][Full Text] [Related]
38. Dopaminergic manipulations and its effects on neurogenesis and motor function in a transgenic mouse model of Huntington's disease. Choi ML; Begeti F; Oh JH; Lee SY; O'Keeffe GC; Clelland CD; Tyers P; Cho ZH; Kim YB; Barker RA Neurobiol Dis; 2014 Jun; 66():19-27. PubMed ID: 24561069 [TBL] [Abstract][Full Text] [Related]
39. An open system for automatic home-cage behavioral analysis and its application to male and female mouse models of Huntington's disease. Zarringhalam K; Ka M; Kook YH; Terranova JI; Suh Y; King OD; Um M Behav Brain Res; 2012 Apr; 229(1):216-25. PubMed ID: 22266926 [TBL] [Abstract][Full Text] [Related]
40. Evaluation of R6/2 HD transgenic mice for therapeutic studies in Huntington's disease: behavioral testing and impact of diabetes mellitus. Lüesse HG; Schiefer J; Spruenken A; Puls C; Block F; Kosinski CM Behav Brain Res; 2001 Nov; 126(1-2):185-95. PubMed ID: 11704263 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]